Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia.

At a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total shareholder return of 87.13% and 3 year total shareholder return of 33.27% indicate that recent momentum follows a much weaker longer term experience.

If you are looking beyond a single biotech name, this can be a time to broaden your watchlist with other healthcare names using our screener for 35 healthcare AI stocks.

With Iovance trading at $3.69 after a sharp 30 day rebound, yet still carrying a loss of $390.978 million and a value score of 4, is the current price an attractive valuation or has the market already accounted for these factors?

Most Popular Narrative: 55.8% Undervalued

Against a last close of $3.69, the most widely followed narrative assigns Iovance Biotherapeutics a fair value of $8.35, using a 7.15% discount rate to weigh future cash flows against today’s price.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue ramp and margin shift would need to sit behind an $8.35 fair value and a high implied earnings multiple? The core assumptions here lean heavily on rapid top line expansion, a swing into positive profitability, and a valuation multiple that usually belongs to faster growing sectors. The full narrative spells out how those pieces fit together and how sensitive that outcome is to even small changes in those inputs.

Result: Fair Value of $8.35 (UNDERVALUED)

However, this hinges on key uncertainties, especially regulatory setbacks such as the withdrawn EMA filing for Amtagvi and the company’s heavy dependence on a single high priced therapy.

Another Angle On The Price Tag

The first narrative leans heavily on a discounted cash flow output of $8.35, which points to Iovance trading on a wide discount. Yet on a simple P/S lens, the picture is less clear. The current P/S is 5.8x versus a fair ratio of 4.2x and a US Biotechs average of 10.6x, so the stock screens cheaper than peers but richer than the level our models suggest the market could move toward. For investors, that tension raises a key question: is the DCF optimism or the revenue multiple caution closer to how you see the next few years playing out?

For a revenue based view, it is worth checking how the current pricing stacks up against detailed ratio work in the full valuation breakdown. This walks through the gap between the present 5.8x P/S, the 4.2x fair ratio and the broader 10.6x sector context in more detail, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals in this story, it can pay to review the numbers yourself and decide quickly where you stand on the balance of risks and rewards, starting with the 2 key rewards and 3 important warning signs.

Ready to widen your opportunity set?

If you stop with a single stock, you risk missing ideas that better fit your goals, time horizon, and comfort with risk.

• Target potential mispricings by scanning a focused list of quality names that look cheap on the numbers using the 53 high quality undervalued stocks.
• Prioritise resilience by reviewing companies that pair robust finances with steadier risk profiles through the 68 resilient stocks with low risk scores.
• Get a head start on tomorrow’s potential leaders by working through a screener containing 26 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.